UK – Positive results for GSK/CureVac’s COVID-19 vaccine

A second-generation mRNA-based COVID-19 vaccine, developed as part of a collaboration between GlaxoSmithKline (GSK) and CureVac, has yielded some positive results in preclinical testing.

The vaccine candidate – CV2CoV – has been developed as part of a collaboration announced by GSK and CureVac in February.

The partnership is focusing on developing a novel mRNA-based COVID-19 vaccine by using multivalent and monovalent approaches to offer broader protection against newly emerging variants.

In an early study, the next-generation mRNA vaccine induced high levels of antigen production and strong immune responses in vaccinated animal subjects.

The data also showed that CV2CoV was able to generate significant cross-neutralisation against a number of COVID-19 variants, including the B.1.1.298 (first discovered in Denmark), the B.1.1.7 (first discovered in the UK) and B.1.351 (first discovered in South Africa) variants…